Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preclinical Evaluation of <sup>177</sup>Lu-Labeled Anti-CLDN18.2 VHH-Fc for Radioimmunotherapy in Gastric Cancer.

Molecular pharmaceutics·2026
Same author

Development and Evaluation of an Albumin-Binding GPC3-Targeting Peptide for PET Imaging of Hepatocellular Carcinoma.

Molecular pharmaceutics·2026
Same author

Characteristics and prognostic value of pre-treatment <sup>18</sup>F-FDG PET in neuroblastoma.

European journal of nuclear medicine and molecular imaging·2026
Same author

Helper lipid-engineered extracellular vesicles enable PET imaging-guided pulmonary siRNA delivery to treat lung metastasis.

Science advances·2026
Same author

Correction to "Detection of Voltage-Gated Potassium Channels 1.3 via Immuno-PET Visualizes Rheumatoid Arthritis".

Molecular pharmaceutics·2026
Same author

Design, Synthesis, and Evaluation of OncoFAP Derivatives with the Albumin Binder as Novel Antitumor Radiopharmaceuticals.

Chemical & biomedical imaging·2026

Related Experiment Video

Updated: May 12, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K

Peptide-Based PET Imaging Differentiates Netrin-1 Expression in Tumors.

Jingwen Wang1,2,3, Lixia Feng1,2,3, Xingru Long1,2,3

  • 1Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

Molecular Pharmaceutics
|June 23, 2025
PubMed
Summary

A novel Gallium-68 labeled peptide, [Ga-68]Ga-DKP, was developed to image neuroaxonal guidance factor-1 (Netrin-1) in tumors. This tracer shows promise for quantifying Netrin-1 expression and aiding in cancer theranostics.

Keywords:
Ga-68PET/CT imagingneuroaxonal guidance factor-1nuclear medicine

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

9.1K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.6K

Related Experiment Videos

Last Updated: May 12, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K
In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

9.1K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.6K

Area of Science:

  • Biomedical imaging
  • Radiochemistry
  • Oncology

Background:

  • Neuroaxonal guidance factor-1 (Netrin-1) is a secreted glycoprotein implicated in tumor growth and metastasis.
  • Netrin-1 shows potential as a biomarker for tumor theranostics.
  • Accurate assessment of Netrin-1 expression is crucial for cancer management.

Purpose of the Study:

  • To develop and evaluate a novel Gallium-68 labeled peptide radiotracer, [Ga-68]Ga-DKP, for imaging Netrin-1 expression.
  • To assess the tracer's specificity and efficacy in preclinical cancer models.
  • To explore the potential of [Ga-68]Ga-DKP for clinical theranostic applications.

Main Methods:

  • Development of a Gallium-68 labeled peptide ([Ga-68]Ga-DKP).
  • In vitro cellular assays using A549, 4T1, and A375 cell lines to assess binding affinity and specificity.
  • In vivo Positron Emission Tomography/Computed Tomography (PET/CT) imaging and biodistribution studies in tumor-bearing mice.

Main Results:

  • The [Ga-68]Ga-DKP tracer demonstrated high radiochemical purity (>95%) and stability.
  • In vitro assays confirmed higher Netrin-1 expression and probe binding in A549 and 4T1 cells compared to A375 cells.
  • In vivo studies showed rapid tumor uptake and favorable tumor-to-muscle ratios in A549 and 4T1 tumor models.

Conclusions:

  • [Ga-68]Ga-DKP is a specific and effective radiotracer for quantifying Netrin-1 expression.
  • The tracer exhibits potential for clinical application in cancer theranostics.
  • This imaging approach could improve personalized cancer treatment strategies.